González-Juanatey J R, García-Acuña J M, Calvo Gómez C, Amaro Cendón A, Fernández-López J A, Gil de la Peña M
Servicio de Cardiología y Unidad Coronaria, Unidad de Hipertensión, Hospital Xeral de Galicia-Clínico Universitario, Santiago de Compostela, La Coruña.
Rev Esp Cardiol. 1994 Jun;47(6):375-83.
To evaluate the effect of two calcium antagonists (verapamil and nitrendipine) on the regression of left ventricular mass and function (systolic and diastolic) by echocardiography-Doppler, in not treated hypertensive subjects.
31 hypertensive subjects were studied in a randomized, placebo controlled, prospective and double blind trial. Verapamil (120-240 mg/day) was administered in 16 and nitrendipine (10-20 mg/day) in 15. The active drug therapy phase was 12 months with rest and effort tensional evaluation. Echo-Doppler was performed in the placebo phase, 6 and 12 months, evaluating left ventricular structure (septal and posterior-wall thicknesses, diameters and mass) and function (systolic and diastolic).
Tensional control at rest and under effort was similar with both drugs, heart rate decreased only with verapamil. Left ventricular mass index decreased with verapamil and nitrendipine, due to reduction in the wall thicknesses (with verapamil from 158.5 +/- 31 to 135.7 +/- 20 g/m2 and with nitrendipine from 167.3 +/- 26 to 146.9 +/- 21 g/m2, p < 0.05). Left ventricular systolic function was not modified during the follow-up with both drugs. Only in the verapamil group some left ventricular diastolic function parameters improved (E from 0.82 +/- 0.11 to 0.95 +/- 0.14 and E/A/Age from 0.013 +/- 0.005 to 0.017 +/- 0.005; p < 0.05).
Verapamil and nitrendipine exerts a similar tensional control at rest and under effort and left ventricular mass regression. The improvement of some diastolic function parameters in the verapamil group was probably due to bradycardia.
通过超声心动图 - 多普勒评估两种钙拮抗剂(维拉帕米和尼群地平)对未经治疗的高血压患者左心室质量及功能(收缩和舒张功能)消退的影响。
在一项随机、安慰剂对照、前瞻性双盲试验中研究了31名高血压患者。16名患者服用维拉帕米(120 - 240毫克/天),15名患者服用尼群地平(10 - 20毫克/天)。积极药物治疗阶段为12个月,并进行静息和运动时的血压评估。在安慰剂阶段、6个月和12个月时进行超声心动图 - 多普勒检查,评估左心室结构(室间隔和后壁厚度、直径和质量)和功能(收缩和舒张功能)。
两种药物在静息和运动时的血压控制相似,仅维拉帕米使心率降低。维拉帕米和尼群地平使左心室质量指数降低,原因是壁厚度减小(维拉帕米组从158.5±31降至135.7±20克/平方米,尼群地平组从167.3±26降至146.9±21克/平方米,p<0.05)。两种药物随访期间左心室收缩功能未改变。仅维拉帕米组一些左心室舒张功能参数有所改善(E从0.82±0.11升至0.95±0.14,E/A/年龄从0.013±0.005升至0.017±0.005;p<0.05)。
维拉帕米和尼群地平在静息和运动时的血压控制及左心室质量消退方面作用相似。维拉帕米组一些舒张功能参数的改善可能归因于心动过缓。